Search research articles
Contact Us
Filters
Showing results (191-200 of 440) with videos related to
Page
of 44
Sort By:
Blood Cells, Molecules & Diseases
|
November 6, 2004
Facilitating T-cell immune reconstitution after haploidentical transplantation in adults
Edmund K Waller, Cynthia R Giver, Hilary Rosenthal, et al.
Cancer Biology & Therapy
|
June 2, 2016
Dual inhibition of Mcl-1 by the combination of carfilzomib and TG02 in multiple myeloma
Katelyn G Ponder, Shannon M Matulis, Sadae Hitosugi, et al.
British Journal of Haematology
|
May 4, 2011
Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study
Paul G Richardson, Asher A Chanan-Khan, Sagar Lonial, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
May 9, 2025
Feasibility and Safety of Outpatient Model for Administration of Bispecific Antibodies: Proceedings from an International Myeloma Society 21st Annual Meeting Oral Abstract
Sara A Scott, Danielle L Roberts, Vikas A Gupta, et al.
Blood
|
June 11, 2011
Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1-expressing myeloma cells
Alejo A Morales, Metin Kurtoglu, Shannon M Matulis, et al.
The Annals of Pharmacotherapy
|
November 22, 2013
Subcutaneous versus intravenous bortezomib: efficiency practice variables and patient preferences
Meagan S Barbee, R Donald Harvey, Sagar Lonial, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
July 18, 2021
Daratumumab Plus Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
Andrzej Jakubowiak, Saad Z Usmani, Amrita Krishnan, et al.
Blood Cancer Journal
|
December 4, 2025
Final OS analyses from the TOURMALINE- MM3 and -MM4 RCTs of ixazomib maintenance in newly diagnosed multiple myeloma
Meletios A Dimopoulos, Sagar Lonial, Wee-Joo Chng, et al.
Haematologica
|
September 4, 2025
Infection risk in 158 patients with relapsed/refractory multiple myeloma treated with bispecific antibodies: a single-center experience
Lorenzo Cani, Sara A Scott, Danielle Roberts, et al.
Clinical Pharmacokinetics
|
November 30, 2016
Pharmacokinetics of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma After Prior Proteasome Inhibitor and Immunomodulatory Drug Treatment
Pamela L Clemens, Xiaoyu Yan, Henk M Lokhorst, et al.
Page
of 44
Search research articles
Search
Showing results (191-200 of 440) with videos related to
Sort By:
Page
of 44
Blood Cells, Molecules & Diseases
|
November 6, 2004
Facilitating T-cell immune reconstitution after haploidentical transplantation in adults
Edmund K Waller, Cynthia R Giver, Hilary Rosenthal, et al.
Cancer Biology & Therapy
|
June 2, 2016
Dual inhibition of Mcl-1 by the combination of carfilzomib and TG02 in multiple myeloma
Katelyn G Ponder, Shannon M Matulis, Sadae Hitosugi, et al.
British Journal of Haematology
|
May 4, 2011
Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study
Paul G Richardson, Asher A Chanan-Khan, Sagar Lonial, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
May 9, 2025
Feasibility and Safety of Outpatient Model for Administration of Bispecific Antibodies: Proceedings from an International Myeloma Society 21st Annual Meeting Oral Abstract
Sara A Scott, Danielle L Roberts, Vikas A Gupta, et al.
Blood
|
June 11, 2011
Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1-expressing myeloma cells
Alejo A Morales, Metin Kurtoglu, Shannon M Matulis, et al.
The Annals of Pharmacotherapy
|
November 22, 2013
Subcutaneous versus intravenous bortezomib: efficiency practice variables and patient preferences
Meagan S Barbee, R Donald Harvey, Sagar Lonial, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
July 18, 2021
Daratumumab Plus Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
Andrzej Jakubowiak, Saad Z Usmani, Amrita Krishnan, et al.
Blood Cancer Journal
|
December 4, 2025
Final OS analyses from the TOURMALINE- MM3 and -MM4 RCTs of ixazomib maintenance in newly diagnosed multiple myeloma
Meletios A Dimopoulos, Sagar Lonial, Wee-Joo Chng, et al.
Haematologica
|
September 4, 2025
Infection risk in 158 patients with relapsed/refractory multiple myeloma treated with bispecific antibodies: a single-center experience
Lorenzo Cani, Sara A Scott, Danielle Roberts, et al.
Clinical Pharmacokinetics
|
November 30, 2016
Pharmacokinetics of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma After Prior Proteasome Inhibitor and Immunomodulatory Drug Treatment
Pamela L Clemens, Xiaoyu Yan, Henk M Lokhorst, et al.
Page
of 44